Matthew Murphy compensation by year
Nautilus Biotechnology Summary Compensation Table · the one fiscal year held| Component | FY2021 |
|---|---|
| Salary | $231,096 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $2,484,767 |
| Non-equity incentive | $74,344 |
| Pension and deferred compensation | $0 |
| All other | $250 |
| Total | $2,790,457 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Nautilus Biotechnology, Inc. DEF 14A filed April 28, 2022, accession 0001808805-22-000041, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Nautilus Biotechnology, Inc. filed document, accession 0001808805-22-000041. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 326,526 | — | $10.10 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Nautilus Biotechnology, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2021 proxy (filed April 28, 2022)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-03-02 | Grant or award derivative | — | 160,000 | $0.00 | 160,000 |
| 2025-09-04 | Purchase | — | 20,000 | $0.64 | 74,140 |
| 2025-03-03 | Grant or award derivative | — | 160,000 | $0.00 | 160,000 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Nautilus Biotechnology’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Sujal Patel | President, Chief Executive Officer and Secretary | $6,605,335 |
| Parag Mallick | Chief Scientist | $3,999,510 |
| Matthew Murphy · this page | General Counsel | $2,790,457 |
The full Nautilus Biotechnology compensation record
free company briefThis page is one person within Nautilus Biotechnology's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Nautilus Biotechnology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.